Amlenetug not checked
H. Lundbeck A/S · Lu AF82422
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- Tested for
- Multiple System Atrophy (2 trials)
- Main trialPhase 3
- “The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).”In the company’s words, NCT06706622 on ClinicalTrials.gov
- Other names
- Lu AF82422
Other drugs for Multiple System Atrophy
Coming up1
- 17 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 17 Feb 2028 | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) | |
| Phase 2Active, not recruiting | 16 Nov 2023 | A Study of Lu AF82422 in Participants With Multiple System Atrophy | |
| Phase 1Completed | 26 Jul 2021 | Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease | |
| Phase 1Completed | 3 Sep 2024 | A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026